From glycosylation disorders back to glycosylation: What have we learned?  by Hennet, Thierry
Biochimica et Biophysica Acta 1792 (2009) 921–924
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbad isReview
From glycosylation disorders back to glycosylation: What have we learned?
Thierry Hennet
Institute of Physiology, University of Zürich, SwitzerlandE-mail address: thennet@access.uzh.ch.
0925-4439/$ – see front matter © 2008 Elsevier B.V. A
doi:10.1016/j.bbadis.2008.10.006a b s t r a c ta r t i c l e i n f oArticle history: Diseases of glycosylation ha
Received 29 August 2008
Accepted 9 October 2008
Available online 22 October 2008
Keywords:
Dystroglycan
Mucin O-glycosylation
Oligosaccharyltransferase
Glucosyltransferase
COG complex
CMP-sialic acidve long remained conﬁned to the rare hematological disorders, the Tn-syndrome
[1] and paroxysmal nocturnal hemoglobinuria ,[2]. This rarity was often interpreted as a sign that defects of
glycosylation are either lethal, or remain asymptomatic because of the large redundancy found in
glycosylation pathways. The description of multiple glycosylation disorders over the last years has
deﬁnitively settled the issue and demonstrated the broad range of biological processes relying on proper
glycosylation. However, beyond establishing the developmental and physiological roles of glycosylation how
did glycosylation disorders provided new insights to the ﬁeld of glycobiology?
© 2008 Elsevier B.V. All rights reserved.Diseases presenting similar clinical features often share common
causes. Suchphenotypic similarities havehelped expanding the inventory
of genes involved in common glycosylation pathways. This was the case
for various forms of congenital muscular dystrophies, which allowed
associating putative glycosyltransferase genes with α-dystroglycan
glycosylation. In other instances, similar clinical features pointed to
relationships between glycosyltransferases and their protein substrates.
Typically, the identiﬁcation of the polypeptide GalNAc-transferase-3
mutationsasa causeof tumorcalcinosis shednewlighton thesigniﬁcance
ofO-GalNacmodiﬁcations in the contextof FGF23 functions. Furthermore,
the identiﬁcation of glycosylation disorders linked to defects of vesicular
transport has advanced the understandingof themechanisms involved in
glycosyltransferase localization. Sometimes, the description of novel
glycosylation disorders yielded unexpected ﬁndings, which raised new
questions on the functions of previously described genes. For example,
mutations in the UDP-GlcNAc-2-epimerase/N-acetylmannosamine
kinase gene caused a relatively mild myopathy, which was strongly in
contrast to the embryonic lethality observed in the corresponding
knockout mouse model. In conclusion, glycosylation disorders can reveal
interesting features of glycoconjugates or open new perspectives on
speciﬁc pathways.
1. Dystroglycan glycosylation
The description of several glycosylation disorders among the family
of congenital muscular dystrophies certainly expanded the visibility
and biological signiﬁcance of the O-mannosylation pathway. Protein
O-mannosylation was long considered to be speciﬁc to fungal cell wallll rights reserved.glycosylation. Whereas O-linked mannosylated glycans had been
documented in multicellular organisms including mammals [3], the
structure of the O-mannosylated chains and the nature of the dedicated
glycosyltransferases have long remained unclear. The description of the
POMGNT1 glycosyltransferase and its association to Muscle–Eye–Brain
disease [4] rapidly brought O-mannosylation to the central stage of
congenital muscular dystrophies. The successive description of FKRT [5],
POMT1 [6], POMT2 [7], LARGE [8] and the reinterpretation of the fukutin
defect [9] deﬁnitively established the importance of α-dystroglycan
glycosylation in the etiology of congenital muscular dystrophies.
Whereas the involvement of the aforementioned proteins in α-
dystroglycan glycosylation is undisputed, to date only POMT and
POMGNT1 have been assigned a clear glycosyltransferase activity.
LARGE, fukutin and FKRP show structural features typical of glycosyl-
transferases but their enzymatic activities remain unknown. Studies
performed in mutant CHO cells have shown that LARGE is capable of
elongating bothO-andN-glycan chains [10]. The presence of two distinct
glucosyltransferase- and N-acetylglucosaminyltransferase-like domains
in LARGE suggests that this protein may have a carbohydrate
polymerizing activity as observed in the biosynthesis of glycosamino-
glycan chains [11,12]. The large carbohydrate moiety of the α-
dystroglycan protein certainly supports this notion. So why have the
activity of LARGE, fukutin and FKRP remained intractable in spite of
numerous efforts? Like for other orphan glycosyltransferases, several
options could account for the missing activity. It could be that these
enzymes require a co-factor that has not been identiﬁed yet. Alterna-
tively, it is possible that these enzymes build heteromeric complexes
with partners that have not been considered yet. It could also be that
theseenzymes transfer carbohydrates to acceptor substratesmodiﬁedby
sulfation or phosphorylation as it hasbeendescribed for the formation of
the glycosaminoglycan tetrasaccharide core [13]. Although the puzzle of
Fig. 1. Glucosylation and deglucosylation of lipid-linked oligosaccharides in the
endoplasmic reticulum. The ALG6, ALG8 and ALG10 glucosyltransferases add each a
Glc residue to the dolichol-pyrophosphate-GlcNAc2Man9 oligosaccharide. The char-
acterization of CDG-Ih has demonstrated that the glucosidase-II (GLS2) enzyme is
capable of deglucosylating LLOs. A similar activity of the glucosidase-I (GLS1) enzyme
on LLOs has not been shown yet.
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defects in congenital muscular dystrophies has allowed grouping some
pieces, i.e. putative glycosyltransferases, around the central ﬁgure of α-
dystroglycan.
2. Mucin O-glycosylation
Mucin-type O-glycosylation is initiated by the transfer of α-linked
GalNAc to the hydroxyl group of serine and threonine. This step is
catalyzed by a family of polypeptide GalNAc-transferases comprising at
least 20members [14]. This multitude of isoformsmakes it challenging to
predict theoutcomeof single enzymedefects. Therefore, the associationof
the polypeptide GalNAc-transferase-3 GALNT3 gene with a form of
tumoral calcinosis [15] came as a surprise. Tumoral calcinosis, a disorder
of calcium and phosphate metabolism, is also caused by mutations in the
FGF23 [16] andKLOTHO [17] genes. The discovery of theGALNT3defect as a
cause of tumoral calcinosis demonstrated the role of O-glycosylation
in the secretion and functions of the FGF23 glycoprotein. In fact, FGF23 is
O-glycosylated and it has been shown that a speciﬁc O-glycan chain
protects the FGF23protein fromcleavage by subtilisin-like proteaseswhile
transiting through the secretorypathway [18]. This case isnotunique since
O-glycosylation has also been shown to protect the intracellular
proteolytic cleavage of the endopeptidase meprin [19] and to be required
for the expression of the LDL receptor [20]. Additional examples are likely
to follow, thereby drawing functional relationships between O-glycosyl-
transferases and speciﬁc glycoproteins. So far, the GALNT3 defect
contributes to establish the importance of O-glycosylation for the
intracellular processing of glycoproteins.
3. Oligosaccharyltransferase
Several disorders of N-glycosylation have been characterized in the
last decade, largely thank to the easy detection of abnormally
glycosylated serum transferrin by isoelectric focusing. Abnormal
transferrin glycosylation was observed for defects of lipid-linked
oligosaccharide (LLO) assembly and for defects of N-glycan proces-
sing. Even defects of glycosyltransferase localization, such as encoun-
tered in COG deﬁciency, affect the N-glycosylation of transferrin.
Whereas most genes of the N-glycosylation pathway encoding ER-
localized proteins have been related to glycosylation disorders, the
oligosaccharyltransferase complex has remained a lonely exception.
This multiprotein complex is expressed ubiquitously and it was
expected that defective oligosaccharyltransferase activity would
result in abnormal transferrin glycosylation. However, the recently
described mutations in the TUSC3/N33 gene [21,22], which encodes
the oligosaccharyltransferase subunit OST3, did not affect the N-
glycosylation of transferrin. The OST3 protein is homologous to the
OST6 subunit and analyses conducted in yeast have shown that OST3
and OST6 form distinct complexes with the other oligosaccharyl-
transferase subunits [23]. OST3 and OST6 are functionally related since
OST3 deﬁciency can be partially rescued by OST6 and vice versa [24].
This functional overlap explains why the deletion of the OST3 gene in
yeast yielded only minor N-glycosylation defects. Along this line, the
normal glycosylation of serum transferrin detected in human OST3
deﬁciency may be related to such a redundancy between OST3 and
OST6. Despite the partial interchangeability of OST3 and OST6, the
association of OST3mutations with nonsyndromic mental retardation
[21,22] demonstrated the unique contribution of OST3 towards
speciﬁc glycoproteins. At the biomedical level, two lessons can be
learned from this result. Firstly, the normal N-glycosylation of serum
transferrin seen in OST3 deﬁciency suggests that additional glycosyla-
tion disorders have certainly remained undiagnosed to date and that
other tests should be developed to detect potential restricted
glycosylation defects. Secondly, the mental retardation phenotype
indicated that OST3 is required for the proper glycosylation and
functions of proteins in the central nervous system. Nonsyndromicmental retardation has also been related to mutations in the CRBN,
CC2D1A, PRSS12 and GRIK2 genes. The latter gene encodes a subunit of
the glutamate receptor, which carries eight N-glycosylation sites. The
phenotypic similarity between the OST3 and GRIK2 defects may
indicate that OST3 is required for GRIK2 expression or activity.
Although representing a difﬁcult task, the description of the OST3
deﬁciency prompted for the search of speciﬁcally underglycosylated
proteins. The characterization of OST3 substrate speciﬁcity would
contribute to a better understanding of the mechanisms underlying
the recognition of glycosylation substrates during protein translation.
4. LLO glucosyltransferases
The comparison of the clinical features linked to different defects
of LLO assembly pointed to a peculiar observation. The last steps of
LLO assembly are catalyzed by the ALG6, ALG8 and ALG10 glucosyl-
transferases (Fig. 1). Whereas ALG6 and ALG8 defects lead to the
accumulation of very similar LLO structures, the clinical outcome of
ALG8 deﬁciency is more severe than that of ALG6 deﬁciency. Themain
features associated to ALG6 deﬁciency, which causes CDG-Ic [25], are
central hypotonia and mild coagulopathy [26]. By contrast, ALG8
deﬁciency, which causes CDG-Ih [27,28], leads to cardio-respiratory
problems, dysmorphism, oedema in addition to a central hypotonia
and coagulopathy as found in CDG-Ic. Most ALG8 patients died in their
infancy, with one exception presenting a mild clinical outcome [28].
What are the reasons for the clinical discrepancy between the ALG6
and ALG8 deﬁciencies? It is possible that the mutations found in the
ALG8 gene lead to a stronger underglycosylation than found in ALG6
deﬁciency. However, the comparison of the level of transferrin
glycosylation between ALG6 and ALG8 deﬁciency does not support
this hypothesis. Alternatively, the different clinical outcome may be
related to different functions of the ALG6 and ALG8 glucosyltrans-
ferases. The characterization of the ALG8 deﬁcient ﬁbroblasts revealed
an unexpected glucosidase activity targeting LLOs. Indeed, ALG8
deﬁciency was accompanied by the accumulation of the incomplete
LLOs dolichyl-pyrophosphate-GlcNAc2Man9 and -GlcNAc2Man9Glc1
[27,28], whereas only the latter structure was expected to accumulate.
This presence of the LLO dolichyl-pyrophosphate-GlcNAc2Man9 in
ALG8-deﬁcient cells indicated that glucosylated LLOs are substrates of
the glucosidase-II enzyme, which removes Glc residues on N-glycans
after they have been transferred to proteins [29]. The accumulation of
incomplete glucosylated LLOs in the ALG8-deﬁcient cells may divert or
impair glucosidase-II activity and thereby worsen the impact of the
ALG8 defect itself on protein glycosylation, folding and secretion.
Although the involvement of glucosidase-II in the pathogenesis of
CDG-Ih is hypothetical at this stage, the question of the distinct
severity between ALG6 and ALG8 deﬁciency shows how the study of
glycosylation disorders lead to new questions and thereby to new
concepts on the mechanisms underlying protein glycosylation.
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The localization of glycosyltransferases is a dynamic process tightly
regulated with the ﬂow of secreted proteins. Recently, defects of
glycosylation have been related to the abnormal assembly of the
Conserved Oligomeric Golgi (COG) complex, which is a tethering
complex involved in vesicular transport. The COG complex is found in
eukaryotes from yeast up to human cells. Although the cellular
functions of COG are still being established, the discovery of COG
defects among glycosylation disorders demonstrated the importance
of COG for proper glycosyltransferase localization. Especially inte-
resting was the strong differences in clinical severity between the COG
defects described to date. In fact, whereas the deﬁciency of the COG7
subunit leads to a multiorgan disorder and to infant mortality in the
index patients [30], the deﬁciency of the COG1 subunit leads to a
milder disease [31]. As discussed by Foulquier et al. [31], this
difference is likely related the speciﬁc involvement of COG subunits
in regulating the localization of Golgi-resident proteins. In any case,
the availability of ﬁbroblast cells from patients with COG deﬁciency
allows a systematic investigation of the role of the COG complex on
the regulation of glycosylation pathways.
6. CMP-sialic acid biosynthesis
The UDP-GlcNAc 2-epimerase/N-acetylmannosamine kinase (GNE)
enzyme catalyzes a rate-limiting step in the synthesis of sialic acid.
Accordingly, GNE activity also correlates with the level of sialylation on
many cell types [32]. Therefore, the association of GNE mutations to a
mild form of neuromuscular disorder called hereditary inclusion body
myopathy (HIBM) [33] was quite surprising. HIBM is characterized by a
late onset myopathy mostly limited to leg muscles. Histological
examination of HIBM tissue revealed typical intramuscular vacuoles
and ﬁlamentous inclusions of unknown origin. By contrast, the
disruption of the GNE gene in mice lead to embryonic lethality [34]
and even the introduction of the frequent GNE mutation M712T by
knockin into the mouse genome has been shown to result in perinatal
lethality [35]. The striking discrepancy between the outcome of GNE
deﬁciency in humans and mice illustrates the different requirement for
sialic acid in both species. This statement does not mean that sialic acid
is dispensable in humans. In fact, the severe hematological disorder
associatedwith a defect of the CMP-sialic acid transporter in a child [36]
supports the essential role of sialylated glycans for human physiology.
The rather weak phenotype of GNE deﬁciency could be related to the
activity of possible salvage pathways that could compensate for the loss
of endogenous sialic acid biosynthesis. At any rate, additional work is
required to understand the relationship between the pathogenesis of
HIBM, the level of residual GNE activity and the contribution of alternate
sources of sialic acid in human biology.
As evident from the examples discussed here, glycosylation
disorders provide new insights on the role of glycosylation in humans
and highlight differences to animal models. Several glycosylation
disorders have been described in the last decade and the list is
certainly going to expand steadily in the years to come. The recent
investigation of N-glycosylation in the context of autoimmune
diseases like multiple sclerosis [37,38] is promising to broaden the
biomedical signiﬁcance of glycosylation even more. The study of
glycosylation disorders has deﬁnitively become an integral part of the
current research landscape on glycosylation. With this concluding
statement, I would also like to remind that this achievement has only
been made possible by the combined efforts of clinicians and
glycobiologists.
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